BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
125 results:

  • 1. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased egfr expression by activating AhR and Akt.
    Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
    Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Machine learning models for predicting the onset of chronic kidney disease after surgery in patients with renal cell carcinoma.
    Oh SW; Byun SS; Kim JK; Jeong CW; Kwak C; Hwang EC; Kang SH; Chung J; Kim YJ; Ha YS; Hong SH
    BMC Med Inform Decis Mak; 2024 Mar; 24(1):85. PubMed ID: 38519947
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study.
    Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Sakuragi M; Uchino E; Hiragi S; Yamamoto S; Sakai K; Matsubara T; Yanagita M; Muto M
    Int J Clin Oncol; 2024 Apr; 29(4):398-406. PubMed ID: 38351273
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
    Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating egfr-dependent AKT pathway activation.
    Liu T; Xiang W; Chen Z; Wang G; Cao R; Zhou F; Meng Z; Luo Y; Chen L
    Cell Death Dis; 2023 Nov; 14(11):774. PubMed ID: 38008826
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. SEL1L3 as a link molecular between renal cell carcinoma and atherosclerosis based on bioinformatics analysis and experimental verification.
    Wang H; Ma X; Li S; Ni X
    Aging (Albany NY); 2023 Nov; 15(22):13150-13162. PubMed ID: 37993256
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Claudin-2 protects against colitis-associated cancer by promoting colitis-associated mucosal healing.
    Ahmad R; Kumar B; Thapa I; Tamang RL; Yadav SK; Washington MK; Talmon GA; Yu AS; Bastola DK; Dhawan P; Singh AB
    J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37815870
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
    Kobayashi G; Hayashi T; Sentani K; Uraoka N; Fukui T; Kido A; Katsuya N; Ishikawa A; Babasaki T; Sekino Y; Nose H; Hinata N; Oue N
    Pathol Int; 2023 Sep; 73(9):444-455. PubMed ID: 37589430
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
    Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
    Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of egfr.
    Luo L; Wei D; Pan Y; Wang QX; Feng JX; Yu B; Kang T; Luo J; Yang J; Gao S
    Cancer Commun (Lond); 2023 Jul; 43(7):808-833. PubMed ID: 37378422
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Impact of Renal Function on the prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
    Takada H; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Muraoka M; Suzuki Y; Sato M; Takano S; Fukasawa M; Yamaguchi T; Maekawa S; Takahashi K; Uchimura K; Enomoto N
    Oncology; 2023; 101(10):609-623. PubMed ID: 37279708
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Association between rapid renal function deterioration and cancer mortality in the elderly: A retrospective cohort study.
    Kuo IC; Chu YC; Chen YH; Chan TC
    Cancer Med; 2023 Apr; 12(8):10008-10019. PubMed ID: 36880220
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via egfr/ERK signaling pathway.
    Xu J; Wang Y; Jiang J; Yin C; Shi B
    J Transl Med; 2023 Jan; 21(1):56. PubMed ID: 36717944
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
    Zhang GT; Liu Q; Zuo FX; Liu HJ; Wang SQ; Yuan Q; Liu AS; Hu K; Meng XL; Wang WJ; Qian HP; Wan JH; Cai HQ
    BMC Cancer; 2023 Jan; 23(1):104. PubMed ID: 36717819
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Acute kidney injury as an independent predicting factor for stage 3 or higher chronic kidney disease after nephrectomy.
    Yang X; Zhang T; Zhou H; Ni Z; Wang Q; Wu J; Chen Q; Qiu M; Wang Y; Fu T; Ye M; Zhang J; Xue W; Mou S
    Urol Oncol; 2023 Mar; 41(3):149.e1-149.e9. PubMed ID: 36463084
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The incidence and risk factors of chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma.
    Wang S; Liu Z; Zhang D; Xiang F; Zheng W
    BMC Cancer; 2022 Nov; 22(1):1138. PubMed ID: 36335288
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/egfr signaling in renal cell carcinoma.
    Li M; Liu G; Jin X; Guo H; Setrerrahmane S; Xu X; Li T; Lin Y; Xu H
    Mol Cancer; 2022 Sep; 21(1):181. PubMed ID: 36117171
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
    Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
    Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
    Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
    Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.